Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein
Intestinal fatty acid binding protein (I-FABP) is present at high levels in the absorptive cells of the intestine (enterocytes) where it plays a role in the intracellular solubilization of fatty acids (FA). However, I-FABP has also been shown to bind to a range of non-FA ligands, including some lipophilic drug molecules, albeit with generally lower affinity than FA. The significance of these lower affinity interactions with exogenous compounds is not known. In this manuscript, we describe further characterization of drug-rat I-FABP binding interactions using a thermal-shift assay. A structural explanation of the observed affinity of rat I-FABP for different drugs based on spectroscopic data and modeling experiments is presented. In addition, immunocytochemistry has been used to probe the expression of I-FABP in a cell culture model reflective of the absorptive cells of the small intestine. Taken together, these data suggest a possible role for I-FABP in the disposition of some lipophilic drugs within the enterocyte.
KeywordsIntestinal drug absorption Drug transport Intestinal fatty acid binding protein Fluorescence-based thermal-shift assay
T. Velkov is the recipient of a Peter Doherty Fellowship (384300) from the National Health and Medical Research Council, Australia. This work was supported by grants from the Australian Research Council (DP0342458, DP0664069).
- 1.Avdeef A (2003) Drug bioavailability: estimation of solubility, permeability, absorption and bioavailability. Wiley-VCH, Weinheim, GermanyGoogle Scholar
- 2.Avdeef A (2003) Absorption and drug development solubility, permeability, and charge state. Wiley-Interscience, Hoboken, NJGoogle Scholar
- 6.Lücke C, Gutiérrez-González LH, Hamilton J (2003) Intracellular lipid binding proteins: evolution, structure and ligand binding. In: Duttaroy AK, Spener F (eds) Cellular proteins and their fatty acids in health and disease. Wiley-VCH, Weinheim, GermanyGoogle Scholar
- 10.Wolfrum C, Borrmann CM, Börchers T, Spener F (2001) Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci USA 98:2323–2328. doi: 10.1073/pnas.051619898 PubMedCrossRefGoogle Scholar
- 15.Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E, Carver T, Asel E, Springer BA, Lane P, Salemme FR (2001) High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 6:429–440. doi: 10.1177/108705710100600609 PubMedCrossRefGoogle Scholar
- 18.Goddard TD, Kneller DG (2006) SPARKY 3. http://www.cgl.ucsf.edu/home/sparky
- 20.DeLano WL (2002) PyMol. http://www.pymol.org
- 24.Storch J, Herr FM, Hsu KT, Kim HK, Liou HL, Smith ER (1996) The role of membranes and intracellular binding proteins in cytosolic transport of hydrophobic molecules: fatty-acid binding proteins. Comp Biochem Physiol 115B:333–339Google Scholar